Amyloid P component as a plasma marker for Parkinson's disease identified by a proteomic approach

Clinical Biochemistry

Volumn 44, Issue 5-6, 2011, Pages 377-385

  Chen, Han Min ^a   Lin, Ching Yu ^a   Wang, Vinchi ^b,c  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b CARDINAL TIEN HOSPITAL   (Taiwan)

^c FU JEN CATHOLIC UNIVERSITY   (Taiwan)

Author keywords

Immunoglobulin G kappa light chain (IgG L); Mass spectrometry (MS); Parkinson's disease (PD); Proteomics; Serum amyloid P component (SAP); Two dimensional electrophoresis (2 DE)

Indexed keywords

AMYLOID P COMPONENT; IMMUNOGLOBULIN KAPPA CHAIN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEOMICS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL ELECTROPHORESIS;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARKINSON DISEASE; PROTEOMICS; SERUM AMYLOID P-COMPONENT;

EID: 79952757411     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2011.01.002     Document Type: Article

References (49)

1. de Rijk M.C., Launer L.J., Berger K., et al. Prevalence of Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000, 54:S21-S23.
2. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann NY Acad Sci 2003, 991:120-131.
3. Aebersold R., Mann M. Mass spectrometry-based proteomics. Nature 2003, 422:198-207.
4. Oba H., Yagishita A., Terada H., et al. New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology 2005, 64:2050-2055.
5. Runne H., Kuhn A., Wild E.J., et al. Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA 2007, 104:14424-14429.
6. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 2000, 3:1301-1306.
7. Di Monte D.A., McCormack A., Petzinger G., Janson A.M., Quik M., Langston W.J. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov Disord 2000, 15:459-466.
8. Hughes A.J., Ben-Shlomo Y., Daniel S.E., Lees A.J. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992, 42:1142-1146.
9. Kalaria R.N., Galloway P.G., Perry G. Widespread serum amyloid P immunoreactivity in cortical amyloid deposits and the neurofibrillary pathology of Alzheimer's disease and other degenerative disorders. Neuropathol Appl Neurobiol 1991, 17:189-201.
10. Tennent G.A., Lovat L.B., Pepys M.B. Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis. Proc Natl Acad Sci USA 1995, 92:4299-4303.
11. Alonso A.D., Grundke-Iqbal I., Barra H.S., Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci USA 1997, 94:298-303.
12. Tokuda T., Salem S.A., Allsop D., et al. Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem Biophys Res Commun 2006, 349:162-166.
13. Lee P.H., Lee G., Park H.J., Bang O.Y., Joo I.S., Huh K. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy. J Neural Transm 2006, 113:1435-1439.
14. Li Q.X., Mok S.S., Laughton K.M., et al. Plasma α-synuclein is decreased in subjects with Parkinson's disease. Exp Neurol 2007, 204:583-588.
15. Kahle P.J., Haass C. How does parkin ligate ubiquitin to Parkinson's disease?. EMBO Rep 2004, 5:681-685.
16. Buneeva O.A., Medvedev A.E. Ubiquitin-protein ligase parkin and its role in the development of Parkinson's disease. Biochemistry (Mosc) 2006, 71:851-860.
17. Griffin T.J., Gygi S.P., Ideker T., et al. Complementary profiling of gene expression at the transcriptome and proteome levels in Saccharomyces cerevisiae. Mol Cell Proteomics 2002, 1:323-333.
18. Banks R.E., Dunn M.J., Hochstrasser D.F., et al. Proteomics: new perspectives, new biomedical opportunities. Lancet 2000, 356:1749-1756.
19. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
20. Simpson R.J. Protein and Proteomics: A Laboratory Manual 2003, Cold Spring Harbor Laboratory Press.
21. Gorg A., Postel W., Gunther S. The current state of two-dimensional electrophoresis with immobilized pH gradients. Electrophoresis 1988, 9:531-546.
22. Nybo M., Olsen H., Jeune B., Andersen-Ranberg K., Holm Nielsen E., Svehag S.E. Increased plasma concentration of serum amyloid P component in centenarians with impaired cognitive performance. Dement Geriatr Cogn Disord 1998, 9:126-129.
23. Rose K., Bougueleret L., Baussant T., et al. Industrial-scale proteomics: from liters of plasma to chemically synthesized proteins. Proteomics 2004, 4:2125-2150.
24. Vidaud C., Dedieu A., Basset C., et al. Screening of human serum proteins for uranium binding. Chem Res Toxicol 2005, 18:946-953.
25. Dayarathna M.K., Hancock W.S., Hincapie M. A two step fractionation approach for plasma proteomics using immunodepletion of abundant proteins and multi-lectin affinity chromatography: Application to the analysis of obesity, diabetes, and hypertension diseases. J Sep Sci 2008, 31:1156-1166.
26. Ahmed N., Barker G., Oliva K., et al. An approach to remove albumin for the proteomic analysis of low abundance biomarkers in human serum. Proteomics 2003, 3:1980-1987.
27. Steel L.F., Trotter M.G., Nakajima P.B., Mattu T.S., Gonye G., Block T. Efficient and specific removal of albumin from human serum samples. Mol Cell Proteomics 2003, 2:262-270.
28. Frangione B., Moloshok T., Solomon A. Primary structure of the variable region of a human lambda VI light chain: Bence Jones protein SUT. J Immunol 1983, 131:2490-2493.
29. Gertz M.A. The classification and typing of amyloid deposits. Am J Clin Pathol 2004, 121:787-789.
30. Sidor M.M., Sakic B., Malinowski P.M., Ballok D.A., Oleschuk C.J., Macri J. Elevated immunoglobulin levels in the cerebrospinal fluid from lupus-prone mice. J Neuroimmunol 2005, 165:104-113.
31. Pepys M.B., Dyck R.F., de Beer F.C., Skinner M., Cohen A.S. Binding of serum amyloid P-component (SAP) by amyloid fibrils. Clin Exp Immunol 1979, 38:284-293.
32. Skinner M., Sipe J.D., Yood R.A., Shirahama T., Cohen A.S. Characterization of P-component (AP) isolated from amyloidotic tissue: half-life studies of human and murine AP. Ann NY Acad Sci 1982, 389:190-198.
33. Shirahama T., Skinner M., Sipe J.D., Cohen A.S. Widespread occurrence of AP in amyloidotic tissues. An immunohistochemical observation. Virchows Arch B Cell Pathol Incl Mol Pathol 1985, 48:197-206.
34. Skinner M., Pepys M.B., Cohen A.S., Heller L.M., Lian J.B. Amyloid and amyloidosis: proceedings of the Third International Symposium on Amyloidosis. Third International Symposium on Amyloidosis; 1980; Póvoa de Varzim 1980, 384-391. Excerpta Medica, Portugal: Amsterdam. F. Antonio Falcão de, G.G. Glenner, P.P. Costa (Eds.).
35. Skinner M., Cohen A.S., Shirahama T., Cathcart E.S. P-component (pentagonal unit) of amyloid: isolation, characterization, and sequence analysis. J Lab Clin Med 1974, 84:604-614.
36. Westermark P., Shirahama T., Skinner M., Noren P., Cohen A.S. Amyloid P-component (protein AP) in localized amyloidosis as revealed by an immunocytochemical method. Histochemistry 1981, 71:171-175.
37. Hawkins P.N., Rossor M.N., Gallimore J.R., Miller B., Moore E.G., Pepys M.B. Concentration of serum amyloid P component in the CSF as a possible marker of cerebral amyloid deposits in Alzheimer's disease. Biochem Biophys Res Commun 1994, 201:722-726.
38. Nishiyama E., Iwamoto N., Kimura M., Arai H. Serum amyloid P component level in Alzheimer's disease. Dementia 1996, 7:256-259.
39. van Vliet E.A., da Costa Araujo S., Redeker S., van Schaik R., Aronica E., Gorter J.A. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 2007, 130:521-534.
40. Chen X., Lan X., Roche I., Liu R., Geiger J.D. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem 2008, 107:1147-1157.
41. Chen X., Ghribi O., Geiger J.D. Caffeine protects against disruptions of the blood-brain barrier in animal models of Alzheimer's and Parkinson's diseases. J Alzheimers Dis 2010, 20(Suppl 1):S127-S141.
42. Plumb J., McQuaid S., Mirakhur M., Kirk J. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002, 12:154-169.
43. Marcon J., Gagliardi B., Balosso S., et al. Age-dependent vascular changes induced by status epilepticus in rat forebrain: implications for epileptogenesis. Neurobiol Dis 2009, 34:121-132.
44. Pepys M.B., Dash A.C., Markham R.E., Thomas H.C., Williams B.D., Petrie A. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol 1978, 32:119-124.
45. Spillantini M.G., Crowther R.A., Jakes R., Hasegawa M., Goedert M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 1998, 95:6469-6473.
46. Alonso A.C., Grundke-Iqbal I., Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 1996, 2:783-787.
47. Verwey N.A., Schuitemaker A., van der Flier W.M., et al. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease. Dement Geriatr Cogn Disord 2008, 26:522-527.
48. Kolstoe S.E., Ridha B.H., Bellotti V., et al. Molecular dissection of Alzheimer's disease neuropathology by depletion of serum amyloid P component. Proc Natl Acad Sci USA 2009, 106:7619-7623.
49. Wang V., Chen S.Y., Chuang T.C., Shan D.E., Soong B.W., Kao M.C. Val-9Ala and Ile+58Thr polymorphism of MnSOD in Parkinson's disease. Clin Biochem 2010, 43:979-982.